BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-68. [PMID: 23836236 DOI: 10.1038/nm.3251] [Cited by in Crossref: 291] [Cited by in F6Publishing: 288] [Article Influence: 32.3] [Reference Citation Analysis]
Number Citing Articles
1 Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses: ISGs in HCV and HBV Infection. J Med Virol 2017;89:388-96. [DOI: 10.1002/jmv.24659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
2 Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 2015;87:1989-99. [PMID: 25989114 DOI: 10.1002/jmv.24270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
3 Stättermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014;39:1059-70. [PMID: 24654629 DOI: 10.1111/apt.12717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
4 Spaan M, Claassen MA, Hou J, Janssen HL, de Knegt RJ, Boonstra A. The Intrahepatic T Cell Compartment Does Not Normalize Years After Therapy-Induced Hepatitis C Virus Eradication. J Infect Dis 2015;212:386-90. [PMID: 25637348 DOI: 10.1093/infdis/jiv059] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
5 Asadi-Saghandi A, Shams A, Eslami G, Mirghanizadeh SA, Eskandari-Nasab E. Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism. Virusdisease 2016;27:369-74. [PMID: 28004016 DOI: 10.1007/s13337-016-0349-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Maini MK, Schurich A. Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance. J Hepatol. 2014;61:459-461. [PMID: 24953024 DOI: 10.1016/j.jhep.2014.06.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Werner JM, Adenugba A, Protzer U. Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC? Transplantation. 2017;101:904-909. [PMID: 27941432 DOI: 10.1097/tp.0000000000001606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
8 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Beaumont E, Roch E, Chopin L, Roingeard P. Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties. PLoS One 2016;11:e0151626. [PMID: 26966906 DOI: 10.1371/journal.pone.0151626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
10 Paolini R, Bernardini G, Molfetta R, Santoni A. NK cells and interferons. Cytokine Growth Factor Rev. 2015;26:113-120. [PMID: 25443799 DOI: 10.1016/j.cytogfr.2014.11.003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 8.8] [Reference Citation Analysis]
11 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
12 Ansari AW, Ahmad F, Meyer-Olson D, Kamarulzaman A, Jacobs R, Schmidt RE. Natural killer cell heterogeneity: cellular dysfunction and significance in HIV-1 immuno-pathogenesis. Cell Mol Life Sci 2015;72:3037-49. [PMID: 25939268 DOI: 10.1007/s00018-015-1911-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
13 Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol 2016;13:11-35. [PMID: 25544499 DOI: 10.1038/cmi.2014.127] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
14 Pollmann J, Rölle A, Hofmann M, Cerwenka A. Hepatitis C Virus and Human Cytomegalovirus-Natural Killer Cell Subsets in Persistent Viral Infections. Front Immunol 2017;8:566. [PMID: 28567042 DOI: 10.3389/fimmu.2017.00566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
15 Zong L, Peng H, Sun C, Li F, Zheng M, Chen Y, Wei H, Sun R, Tian Z. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. Nat Commun. 2019;10:221. [PMID: 30644386 DOI: 10.1038/s41467-018-08096-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
16 Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology. 2019;156:325-337. [PMID: 30367834 DOI: 10.1053/j.gastro.2018.10.032] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 15.0] [Reference Citation Analysis]
17 Nosaka T, Naito T, Hiramatsu K, Ohtani M, Nemoto T, Marusawa H, Ma N, Hiraku Y, Kawanishi S, Yamashita T, Kaneko S, Nakamoto Y. Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. PLoS One. 2017;12:e0185442. [PMID: 28968425 DOI: 10.1371/journal.pone.0185442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Dara L. The Receptor Interacting Protein Kinases in the Liver. Semin Liver Dis 2018;38:73-86. [PMID: 29471568 DOI: 10.1055/s-0038-1629924] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
19 Araujo P, Gonçalves G, Latini F, Ferreira O, Porto LC, Barreto JA, Girao MJ, Diaz RS. KIR and a specific HLA-C gene are associated with susceptibility and resistance to hepatitis B virus infection in a Brazilian population. Cell Mol Immunol 2014;11:609-12. [PMID: 24842861 DOI: 10.1038/cmi.2014.29] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
20 Gokhale NS, Vazquez C, Horner SM. Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol 2014;9:1061-75. [PMID: 25983854 DOI: 10.2217/fvl.14.89] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
21 Barili V, Vecchi A, Rossi M, Montali I, Tiezzi C, Penna A, Laccabue D, Missale G, Fisicaro P, Boni C. Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. Cells 2021;10:2563. [PMID: 34685543 DOI: 10.3390/cells10102563] [Reference Citation Analysis]
22 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
23 Timperi E, Barnaba V. Viral Hepatitides, Inflammation and Tumour Microenvironment. Adv Exp Med Biol 2020;1263:25-43. [PMID: 32588321 DOI: 10.1007/978-3-030-44518-8_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Höner zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, Deterding K, Port K, Mix C, Manns MP, Herrmann E, Wedemeyer H, Kraft ARM, Cornberg M. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. J Infect Dis 2016;214:1492-7. [DOI: 10.1093/infdis/jiw412] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 11.3] [Reference Citation Analysis]
25 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
26 Townsend EC, Zhang GY, Ali R, Firke M, Moon MS, Han MAT, Fram B, Glenn JS, Kleiner DE, Koh C, Heller T. The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. J Gastroenterol Hepatol. 2019;34:764-775. [PMID: 30695096 DOI: 10.1111/jgh.14617] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Inuzuka T, Takahashi K, Chiba T, Marusawa H. Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions. Pathogens. 2014;3:377-389. [PMID: 25437805 DOI: 10.3390/pathogens3020377] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
28 Yang CM, Yoon JC, Park JH, Lee JM. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. PLoS One 2017;12:e0175793. [PMID: 28410411 DOI: 10.1371/journal.pone.0175793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
29 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
30 Li Y, Pan Q, Zhao H. Investigation of the values of CT perfusion imaging and ultrasound elastography in the diagnosis of liver fibrosis. Exp Ther Med 2018;16:896-900. [PMID: 30116343 DOI: 10.3892/etm.2018.6269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Gu Y, Bi Y, Wei H, Li J, Huang Z, Liao C, Liao W, Huang Y. Expression and clinical significance of inhibitory receptor Leukocyte-associated immunoglobulin-like receptor-1 on peripheral blood T cells of chronic hepatitis B patients: A cross-sectional study. Medicine (Baltimore) 2021;100:e26667. [PMID: 34398030 DOI: 10.1097/MD.0000000000026667] [Reference Citation Analysis]
32 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
33 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched. World J Gastroenterol 2021; 27(21): 2771-2783 [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
34 Fu GF, Pan JC, Lin N, Hu HY, Tang WM, Xu JS, Wang XL, Xu XQ, Qiu T, Liu XY, Chen GH, Mahapatra T, Huan XP, Yang HT. siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection. Viral Immunol 2014;27:207-13. [PMID: 24834927 DOI: 10.1089/vim.2013.0126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61:S14-S25. [PMID: 25443342 DOI: 10.1016/j.jhep.2014.06.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 154] [Article Influence: 21.3] [Reference Citation Analysis]
36 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
37 Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, Wedemeyer H. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016;214:1965-1974. [PMID: 27683821 DOI: 10.1093/infdis/jiw457] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 12.7] [Reference Citation Analysis]
38 Li N, Fan X, Wang X, Zhang X, Zhang K, Han Q, Lv Y, Liu Z. Genetic association of polymorphisms at the intergenic region between PRDM1 and ATG5 with hepatitis B virus infection in Han Chinese patients. J Med Virol 2020;92:1198-205. [PMID: 31729038 DOI: 10.1002/jmv.25629] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
39 Wang F, Zhang X, Liu W, Zhou Y, Wei W, Liu D, Wong CC, Sung JJY, Yu J. Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT Pathway. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00186-7. [PMID: 34506952 DOI: 10.1016/j.jcmgh.2021.08.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Holderried TA, Lang PA, Kim HJ, Cantor H. Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection. Proc Natl Acad Sci U S A 2013;110:21089-94. [PMID: 24324159 DOI: 10.1073/pnas.1320999110] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
41 Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. [PMID: 25934462 DOI: 10.1101/cshperspect.a021436] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 15.7] [Reference Citation Analysis]
42 Yoon JC, Yang CM, Song Y, Lee JM. Natural killer cells in hepatitis C: Current progress. World J Gastroenterol 2016; 22(4): 1449-1460 [PMID: 26819513 DOI: 10.3748/wjg.v22.i4.1449] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
43 Huang QT, Wei SS, Zhong M, Hang LL, Xu YY, Cai GX, Liu Q, Yu YH. Chronic hepatitis B infection and risk of preterm labor: a meta-analysis of observational studies. J Clin Virol. 2014;61:3-8. [PMID: 24973811 DOI: 10.1016/j.jcv.2014.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
44 Pietschmann T, Brown RJP. Hepatitis C Virus. Trends Microbiol. 2019;27:379-380. [PMID: 30709707 DOI: 10.1016/j.tim.2019.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
45 zur Hausen H, de Villiers EM. Cancer "causation" by infections--individual contributions and synergistic networks. Semin Oncol 2014;41:860-75. [PMID: 25499643 DOI: 10.1053/j.seminoncol.2014.10.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
46 Nandi M, Pal S, Ghosh S, Chakraborty BC, Dey D, Baidya A, Shil A, Chattopadhyaya S, Banerjee S, Santra A, Chowdhury A, Datta S. CD8+CD28- T cells: key cytotoxic players impacting disease pathogenesis in chronic HBV infection. Clin Sci (Lond) 2019;133:1917-34. [PMID: 31477625 DOI: 10.1042/CS20190369] [Reference Citation Analysis]
47 Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol 2019;10:2048. [PMID: 31507621 DOI: 10.3389/fimmu.2019.02048] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
48 Mazzolini G, Sowa J, Canbay A. Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability. Clinical Science 2016;130:2121-38. [DOI: 10.1042/cs20160035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
49 Ferrari C. HBV and the immune response. Liver Int. 2015;35 Suppl 1:121-128. [PMID: 25529097 DOI: 10.1111/liv.12749] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 15.0] [Reference Citation Analysis]
50 Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol. 2014;Epub ahead of print. [PMID: 25544499 DOI: 10.1038/cmi.2014.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
51 Wang WT, Zhao XQ, Li GP, Chen YZ, Wang L, Han MF, Li WN, Chen T, Chen G, Xu D, Ning Q, Zhao XP. Immune response pattern varies with the natural history of chronic hepatitis B. World J Gastroenterol 2019; 25(16): 1950-1963 [PMID: 31086463 DOI: 10.3748/wjg.v25.i16.1950] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
52 Bai L, Peng H, Hao X, Tang L, Sun C, Zheng M, Liu F, Lian Z, Bai L, Wei H, Sun R, Tian Z. CD8+ T Cells Promote Maturation of Liver-Resident NK Cells Through the CD70-CD27 axis. Hepatology 2019;70:1804-15. [PMID: 31077406 DOI: 10.1002/hep.30757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
53 Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, Brainard DM, Ingiliz P, Lutz T, Boesecke C, Nelson M. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol 2017;2:347-53. [PMID: 28397698 DOI: 10.1016/S2468-1253(17)30003-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
54 Nicolini LA, Zappulo E, Viscoli C, Mikulska M. Management of chronic viral hepatitis in the hematological patient. Expert Rev Anti Infect Ther 2018;16:227-41. [PMID: 29415584 DOI: 10.1080/14787210.2018.1438264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
55 Israelow B, Narbus CM, Sourisseau M, Evans MJ. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 2014;60:1170-9. [PMID: 24833036 DOI: 10.1002/hep.27227] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
56 Zhu S, Li T, Liu B, Xu Y, Sun Y, Wang Y, Wang Y, Shuai L, Chen Z, Allain JP, Li C. Infection of Common Marmosets with GB Virus B Chimeric Virus Encoding the Major Nonstructural Proteins NS2 to NS4A of Hepatitis C Virus. J Virol 2016;90:8198-211. [PMID: 27384651 DOI: 10.1128/JVI.02653-15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
57 Zhang E, Kosinska A, Lu M, Yan H, Roggendorf M. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA. Antiviral Res. 2015;123:193-203. [PMID: 26476376 DOI: 10.1016/j.antiviral.2015.10.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
58 Abdelwahab KS, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol 2016; 22(2): 862-873 [PMID: 26811632 DOI: 10.3748/wjg.v22.i2.862] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
59 Stiglund N, Strand K, Cornillet M, Stål P, Thorell A, Zimmer CL, Näslund E, Karlgren S, Nilsson H, Mellgren G, Fernø J, Hagström H, Björkström NK. Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. Front Immunol 2019;10:1255. [PMID: 31214196 DOI: 10.3389/fimmu.2019.01255] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
60 Yang S, Tian Z, Wu Y, van Velkinburgh JC, Ni B. Pivotal roles of ILCs in hepatic diseases. Int Rev Immunol. 2015;34:509-522. [PMID: 25730441 DOI: 10.3109/08830185.2015.1008631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
61 Lovelace ES, Polyak SJ. Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection. Viruses 2015;7:6218-32. [PMID: 26633463 DOI: 10.3390/v7122933] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
62 Castro V, Ávila-Pérez G, Mingorance L, Gastaminza P. A Cell Culture Model for Persistent HCV Infection. Methods Mol Biol 2019;1911:157-68. [PMID: 30593624 DOI: 10.1007/978-1-4939-8976-8_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
63 Chivero ET, Stapleton JT. Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection. J Gen Virol 2015;96:1521-32. [PMID: 25667328 DOI: 10.1099/vir.0.000086] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
64 Li Y, Wu Y, Zheng X, Cong J, Liu Y, Li J, Sun R, Tian ZG, Wei HM. Cytoplasm-Translocated Ku70/80 Complex Sensing of HBV DNA Induces Hepatitis-Associated Chemokine Secretion. Front Immunol 2016;7:569. [PMID: 27994596 DOI: 10.3389/fimmu.2016.00569] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
65 Hutchinson JA, Weigand K, Adenugba A, Kronenberg K, Haarer J, Zeman F, Riquelme P, Hornung M, Ahrens N, Schlitt HJ, Geissler EK, Werner JM. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers. Front Immunol 2018;9:146. [PMID: 29467758 DOI: 10.3389/fimmu.2018.00146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397-1406. [PMID: 25157983 DOI: 10.1016/j.jhep.2014.08.025] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 11.8] [Reference Citation Analysis]
67 Wang Y, Zhang Z, Ji D, Chen GF, Feng X, Gong LL, Guo J, Li ZW, Chen CF, Zhao BB, Li ZG, Li QJ, Yan HP, Sempowski G, Wang FS, He YW. Regulation of T cell function by microRNA-720. Sci Rep 2015;5:12159. [PMID: 26199080 DOI: 10.1038/srep12159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
68 King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, Kottilil S, Bellgrau D, Rodell T, Apelian D. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One 2014;9:e101904. [PMID: 25051027 DOI: 10.1371/journal.pone.0101904] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
69 Boni C, Lampertico P, Talamona L, Giuberti T, Invernizzi F, Barili V, Fisicaro P, Rossi M, Cavallo MC, Vecchi A. Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology. 2015;62:1697-1709. [PMID: 26361374 DOI: 10.1002/hep.28155] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
70 Kosinska AD, Bauer T, Protzer U. Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol. 2017;23:75-81. [PMID: 28453967 DOI: 10.1016/j.coviro.2017.03.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
71 Dale JM, Hood SP, Bowen O, Bright H, Cutler KL, Berry N, Almond N, Goldin R, Karayiannis P, Rose NJ. Development of hepatic pathology in GBV-B-infected red-bellied tamarins (Saguinus labiatus). J Med Virol 2020. [PMID: 32181899 DOI: 10.1002/jmv.25769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Bakarozi M, Mavropoulos A, Bogdanos DP, Dalekos GN, Rigopoulou EI. p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. J Viral Hepat 2020;27:52-60. [PMID: 31520461 DOI: 10.1111/jvh.13209] [Reference Citation Analysis]
73 Hu J, Protzer U, Siddiqui A. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. J Virol 2019;93:e01032-19. [PMID: 31375584 DOI: 10.1128/JVI.01032-19] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
74 Ansari AW, Schmidt RE, Shankar EM, Kamarulzaman A. Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus. J Transl Med 2014;12:341. [PMID: 25528160 DOI: 10.1186/s12967-014-0341-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
75 Cao W, Li M, Zhang L, Lu Y, Wu S, Shen G, Chang M, Liu R, Gao Y, Hao H, Hu L, Yi W, Pan CQ, Xie Y. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. Biomed Res Int 2021;2021:2178143. [PMID: 33575322 DOI: 10.1155/2021/2178143] [Reference Citation Analysis]
76 Ivics Z, Amberger M, Zahn T, Hildt E. [Immunotherapies for the treatment of chronic hepatitis B virus infections-an overview with a focus on CAR T cells]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1357-64. [PMID: 32995895 DOI: 10.1007/s00103-020-03223-7] [Reference Citation Analysis]
77 Shiina M, Yamada N, Sugiyama R, Murayama A, Aly HH, Muramatsu M, Wakita T, Imawari M, Kato T. Hepatitis B Virus Genotype-Dependent Vulnerability of Infected Cells to Immune Reaction in the Early Phase of Infection. Front Microbiol 2019;10:2427. [PMID: 31681253 DOI: 10.3389/fmicb.2019.02427] [Reference Citation Analysis]
78 Nakamura I, Furuichi Y, Sugimoto K. Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients. Hepatol Res 2018;48:855-61. [PMID: 29732688 DOI: 10.1111/hepr.13186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
79 Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594. e1. [PMID: 25066692 DOI: 10.1053/j.gastro.2014.06.043] [Cited by in Crossref: 406] [Cited by in F6Publishing: 399] [Article Influence: 50.8] [Reference Citation Analysis]
80 Ishibashi M, Yamaguchi H, Hirotani Y, Sakurada A, Endo T, Sugitani M, Takayama T, Makishima M, Esumi M. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. Arch Virol 2018;163:855-65. [PMID: 29248968 DOI: 10.1007/s00705-017-3675-8] [Reference Citation Analysis]
81 Mondelli MU. Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C. Gastroenterology 2015;149:25-8. [PMID: 26021236 DOI: 10.1053/j.gastro.2015.05.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
82 Fu B, Wang D, Shen X, Guo C, Liu Y, Ye Y, Sun R, Li J, Tian Z, Wei H. Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24+CD38hi B Cells. Front Immunol 2020;11:591269. [PMID: 33424840 DOI: 10.3389/fimmu.2020.591269] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Kratzer R, Sansas B, Lélu K, Evlachev A, Schmitt D, Silvestre N, Inchauspé G, Martin P. A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model. Hum Vaccin Immunother 2018;14:1417-22. [PMID: 29388874 DOI: 10.1080/21645515.2018.1433970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
84 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
85 Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients. J Viral Hepat. 2016;23:267-273. [PMID: 26554542 DOI: 10.1111/jvh.12488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
86 Xu W, Wang NR, Wang HF, Feng Q, Deng J, Gong ZQ, Sun J, Lou XL, Yu XF, Zhou L, Hu JP, Huang XF, Qi XQ, Deng YJ, Gong R, Guo Y, Wang MM, Xiao JC, Deng H. Analysis of epithelial-mesenchymal transition markers in the histogenesis of hepatic progenitor cell in HBV-related liver diseases. Diagn Pathol 2016;11:136. [PMID: 27881141 DOI: 10.1186/s13000-016-0587-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
87 Endig J, Buitrago-molina LE, Marhenke S, Reisinger F, Saborowski A, Schütt J, Limbourg F, Könecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, Clavel T, Haller D, Unger K, Finegold M, Weber A, Manns MP, Longerich T, Heikenwälder M, Vogel A. Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. Cancer Cell 2016;30:308-23. [DOI: 10.1016/j.ccell.2016.06.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
88 Smith C, Khanna R. Immune-based therapeutic approaches to virus-associated cancers. Curr Opin Virol 2018;32:24-9. [PMID: 30241042 DOI: 10.1016/j.coviro.2018.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
90 Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019;10:1507. [PMID: 30944315 DOI: 10.1038/s41467-019-09212-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
91 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
93 Zhang G, Li N, Li Z, Zhu Q, Li F, Yang C, Han Q, Lv Y, Zhou Z, Liu Z. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget. 2015;6:18933-18944. [PMID: 25895129 DOI: 10.18632/oncotarget.3662] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
94 Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol 2019;54:1096-105. [PMID: 31134334 DOI: 10.1007/s00535-019-01594-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Altomonte J, Ebert O. Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma. Front Oncol 2014;4:85. [PMID: 24795862 DOI: 10.3389/fonc.2014.00085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
96 Bender D, Hildt E. Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis. Int J Mol Sci 2019;20:E4659. [PMID: 31546975 DOI: 10.3390/ijms20184659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
97 Straub T, Pircher H. Enhancing immunity prevents virus-induced T-cell-mediated immunopathology in B cell-deficient mice. Eur J Immunol 2019;49:782-9. [PMID: 30793761 DOI: 10.1002/eji.201847962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 de Groen RA, Hou J, van Oord GW, Groothuismink ZM, van der Heide M, de Knegt RJ, Boonstra A. NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection. Antiviral Research 2017;140:18-24. [DOI: 10.1016/j.antiviral.2017.01.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
99 Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73:409-422. [PMID: 32333923 DOI: 10.1016/j.jhep.2020.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
100 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
101 Aono S, Tatsumi T, Yoshioka T, Tawara S, Nishio A, Onishi Y, Fukutomi K, Nakabori T, Kodama T, Shigekawa M, Hikita H, Sakamori R, Takahashi T, Suemizu H, Takehara T. Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice. Biochem Biophys Res Commun 2018;503:1457-64. [PMID: 30033102 DOI: 10.1016/j.bbrc.2018.07.063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Hou H, Kang Y, Zeng Y, Li Y, Shang J. Interleukin-7 augments CD8+ T cells function and promotes viral clearance in chronic hepatitis C virus infection. Cytokine 2018;102:26-33. [PMID: 29275010 DOI: 10.1016/j.cyto.2017.12.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
103 Cangelosi Q, Means SA, Ho H. A multi-scale spatial model of hepatitis-B viral dynamics. PLoS One 2017;12:e0188209. [PMID: 29216213 DOI: 10.1371/journal.pone.0188209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
104 Li Y, Zeng Y, Zeng G, Li J, Zhang X, Cai Q, Chen Y, Lin CS. The effects of direct-acting antiviral agents on the frequency of myeloid-derived suppressor cells and natural killer cells in patients with chronic hepatitis C. J Med Virol 2019;91:278-86. [PMID: 30171691 DOI: 10.1002/jmv.25302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
105 Huang H, Wang J, Li W, Chen R, Chen X, Zhang F, Xu D, Lu F. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol 2018;99-100:71-8. [PMID: 29353073 DOI: 10.1016/j.jcv.2017.12.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
106 Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-691. [PMID: 27210429 DOI: 10.1016/j.jhep.2016.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
107 Liu X, Wan T, Dang S, Wang D, Jiang C, Su Y, Shen M, Tang X, Li X, Li B, Wen L, Feng Q. HLA-DQB1/DRB1 Alleles Associate with Traditional Chinese Medicine Syndrome of Chronic Hepatitis B: A Potential Predictor of Progression. Biomed Res Int 2019;2019:8146937. [PMID: 31871943 DOI: 10.1155/2019/8146937] [Reference Citation Analysis]
108 Xu Y, Wang Z, Du X, Liu Y, Song X, Wang T, Tan S, Liang X, Gao L, Ma C. Tim-3 blockade promotes iNKT cell function to inhibit HBV replication. J Cell Mol Med 2018;22:3192-201. [PMID: 29602251 DOI: 10.1111/jcmm.13600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
109 Larrubia JR, Moreno-Cubero E, Miquel J, Sanz-de-Villalobos E. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015; 21(12): 3480-3491 [PMID: 25834312 DOI: 10.3748/wjg.v21.i12.3480] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
110 Ochel A, Cebula M, Riehn M, Hillebrand U, Lipps C, Schirmbeck R, Hauser H, Wirth D. Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes. Cell Mol Immunol 2016;13:805-15. [PMID: 26412123 DOI: 10.1038/cmi.2015.80] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
111 Pfaender S, Cavalleri JM, Walter S, Doerrbecker J, Campana B, Brown RJ, Burbelo PD, Postel A, Hahn K, Anggakusuma N. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses. Hepatology. 2015;61:447-459. [PMID: 25212983 DOI: 10.1002/hep.27440] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
112 Serti E, Werner JM, Chattergoon M, Cox AL, Lohmann V, Rehermann B. Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology 2014;147:209-220.e3. [PMID: 24685721 DOI: 10.1053/j.gastro.2014.03.046] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 7.3] [Reference Citation Analysis]
113 Du Y, Broering R, Li X, Zhang X, Liu J, Yang D, Lu M. In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application. Front Immunol 2021;12:766534. [PMID: 34777385 DOI: 10.3389/fimmu.2021.766534] [Reference Citation Analysis]
114 Nishio A, Tatsumi T, Nawa T, Suda T, Yoshioka T, Onishi Y, Aono S, Shigekawa M, Hikita H, Sakamori R. CD14+ monocyte-derived galectin-9 induces natural killer cell cytotoxicity in chronic hepatitis C. Hepatology. 2017;65:18-31. [PMID: 27640362 DOI: 10.1002/hep.28847] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
115 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 12.2] [Reference Citation Analysis]
116 Wieland SF. The chimpanzee model for hepatitis B virus infection. Cold Spring Harb Perspect Med 2015;5:a021469. [PMID: 26033082 DOI: 10.1101/cshperspect.a021469] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
117 Jinno A, Park PW. Role of glycosaminoglycans in infectious disease. Methods Mol Biol 2015;1229:567-85. [PMID: 25325982 DOI: 10.1007/978-1-4939-1714-3_45] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
118 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
119 Zur Hausen H, de Villiers EM. Reprint of: cancer "causation" by infections--individual contributions and synergistic networks. Semin Oncol 2015;42:207-22. [PMID: 25843727 DOI: 10.1053/j.seminoncol.2015.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
120 Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K. Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evol 2016;2:vew024. [PMID: 27774307 DOI: 10.1093/ve/vew024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
121 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
122 Cheng L, Li J, Liu Y, Wang F, Wang S, She W, Wu S, Qi X, Zhou Y, Jiang W. HMGB1-induced autophagy: a new pathway to maintain Treg function during chronic hepatitis B virus infection. Clinical Science 2017;131:381-94. [DOI: 10.1042/cs20160704] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
123 Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737 [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
124 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 350] [Article Influence: 45.6] [Reference Citation Analysis]
125 Oh JS, Ali AK, Kim S, Corsi DJ, Cooper CL, Lee SH. NK cells lacking FcεRIγ are associated with reduced liver damage in chronic hepatitis C virus infection. Eur J Immunol 2016;46:1020-9. [PMID: 26712042 DOI: 10.1002/eji.201546009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
126 Echebli N, Tchitchek N, Dupuy S, Bruel T, Peireira Bittencourt Passaes C, Bosquet N, Le Grand R, Bourgeois C, Favier B, Cheynier R, Lambotte O, Vaslin B. Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection. PLoS One 2018;13:e0190334. [PMID: 29324751 DOI: 10.1371/journal.pone.0190334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
127 Yoon EL. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Korean J Gastroenterol 2019;74:258-66. [PMID: 31765554 DOI: 10.4166/kjg.2019.74.5.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. [PMID: 30213667 DOI: 10.1016/j.mam.2018.09.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 127] [Article Influence: 30.3] [Reference Citation Analysis]
129 Hammerich L, Tacke F. Role of gamma-delta T cells in liver inflammation and fibrosis. World J Gastrointest Pathophysiol 2014; 5(2): 107-113 [PMID: 24891982 DOI: 10.4291/wjgp.v5.i2.107] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
130 Whittaker E, López-Varela E, Broderick C, Seddon JA. Examining the Complex Relationship Between Tuberculosis and Other Infectious Diseases in Children. Front Pediatr 2019;7:233. [PMID: 31294001 DOI: 10.3389/fped.2019.00233] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
131 Hu CC, Jeng WJ, Chen YC, Fang JH, Huang CH, Teng W, Hsieh YC, Lin YC, Chien RN, Sheen IS, Lin CY. Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction. Sci Rep 2017;7:15280. [PMID: 29127350 DOI: 10.1038/s41598-017-15527-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
132 Krämer B, Finnemann C, Sastre B, Lutz P, Glässner A, Wolter F, Goeser F, Kokordelis P, Kaczmarek D, Nischalke HD, Strassburg CP, Spengler U, Nattermann J. IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C. PLoS One 2016;11:e0162068. [PMID: 27583440 DOI: 10.1371/journal.pone.0162068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
133 Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X, Ren H, Zhang DZ. Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol 2017;14:819-29. [PMID: 27321064 DOI: 10.1038/cmi.2016.28] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
134 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Xu HC, Huang J, Pandyra AA, Lang E, Zhuang Y, Thöns C, Timm J, Häussinger D, Colonna M, Cantor H, Lang KS, Lang PA. Lymphocytes Negatively Regulate NK Cell Activity via Qa-1b following Viral Infection. Cell Rep 2017;21:2528-40. [PMID: 29186689 DOI: 10.1016/j.celrep.2017.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
136 Ye Y, Liu J, Lai Q, Zhao Q, Peng L, Xie C, Zhang G, Zhang S, Zhang Y, Zhu J, Huang Y, Hu Z, Xie D, Lin B, Gao Z. Decreases in activated CD8+ T cells in patients with severe hepatitis B are related to outcomes. Dig Dis Sci. 2015;60:136-145. [PMID: 25081223 DOI: 10.1007/s10620-014-3297-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
137 Xuan Hoan N, Thi Minh Huyen P, Dinh Tung B, Phuong Giang D, Tat Trung N, Tien Sy B, Thi Tuan N, Thi Ngoc Dung D, Reddy Pallerla S, Velavan TP, Hong Bang M, Huu Song L. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression. Gene 2022;806:145935. [PMID: 34478821 DOI: 10.1016/j.gene.2021.145935] [Reference Citation Analysis]
138 Böttcher K, Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev 2017;121:3-8. [PMID: 28600202 DOI: 10.1016/j.addr.2017.05.016] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 10.4] [Reference Citation Analysis]
139 Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, Martinez-Lopez E, Roman S, Panduro A. Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol 2014; 20(13): 3443-3456 [PMID: 24707127 DOI: 10.3748/wjg.v20.i13.3443] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
140 Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP. Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes. Cancers (Basel) 2020;12:E3295. [PMID: 33171788 DOI: 10.3390/cancers12113295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA, Cramp ME. Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users. J Viral Hepat 2017;24:1082-8. [PMID: 28475247 DOI: 10.1111/jvh.12720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
142 Moreno-Cubero E, Larrubia JR. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol 2016; 22(28): 6469-6483 [PMID: 27605882 DOI: 10.3748/wjg.v22.i28.6469] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
143 Holz L, Rehermann B. T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res 2015;114:96-105. [PMID: 25433310 DOI: 10.1016/j.antiviral.2014.11.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
144 Ravens S, Hengst J, Schlapphoff V, Deterding K, Dhingra A, Schultze-Florey C, Koenecke C, Cornberg M, Wedemeyer H, Prinz I. Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. Front Immunol 2018;9:510. [PMID: 29616028 DOI: 10.3389/fimmu.2018.00510] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
145 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Reference Citation Analysis]
146 Khan HA, Ahmad MZ, Khan JA, Arshad MI. Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance. Hepatobiliary Pancreat Dis Int 2017;16:245-56. [PMID: 28603092 DOI: 10.1016/s1499-3872(17)60014-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 6.8] [Reference Citation Analysis]
147 Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat 2015;22:427-32. [DOI: 10.1111/jvh.12309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
148 Billerbeck E, Wolfisberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM. Mouse models of acute and chronic hepacivirus infection. Science 2017;357:204-8. [PMID: 28706073 DOI: 10.1126/science.aal1962] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 17.5] [Reference Citation Analysis]
149 Mak LY, Seto WK, Yuen MF. Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses 2021;13:1169. [PMID: 34207458 DOI: 10.3390/v13061169] [Reference Citation Analysis]
150 Lupberger J, Schaedler S, Peiran A, Hildt E. Identification and characterization of a novel bipartite nuclear localization signal in the hepatitis B virus polymerase. World J Gastroenterol 2013; 19(44): 8000-8010 [PMID: 24307793 DOI: 10.3748/wjg.v19.i44.8000] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
151 Yokoyama Y, Miyagi T, Hikita H, Yoshioka T, Mukai K, Nawa T, Sakamori R, Ohkawa K, Hiramatsu N, Takahashi T, Suemizu H, Ryo A, Tatsumi T, Takehara T. The Hepatitis B Virus Genotype Affects the Persistence of Viral Replication in Immunodeficient NOG Mice. PLoS One 2015;10:e0144775. [PMID: 26658490 DOI: 10.1371/journal.pone.0144775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
152 Zhang Y, Tang J, Tian Z, van Velkinburgh JC, Song J, Wu Y, Ni B. Innate Lymphoid Cells: A Promising New Regulator in Fibrotic Diseases. Int Rev Immunol. 2016;35:399-414. [PMID: 26222510 DOI: 10.3109/08830185.2015.1068304] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
153 Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. [PMID: 24982656 DOI: 10.3389/fimmu.2014.00274] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
154 Wieland D, Kemming J, Schuch A, Emmerich F, Knolle P, Neumann-Haefelin C, Held W, Zehn D, Hofmann M, Thimme R. TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation. Nat Commun 2017;8:15050. [PMID: 28466857 DOI: 10.1038/ncomms15050] [Cited by in Crossref: 111] [Cited by in F6Publishing: 105] [Article Influence: 22.2] [Reference Citation Analysis]
155 Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep 2016;6:22995. [PMID: 26965318 DOI: 10.1038/srep22995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
156 Lu H, Li DJ, Jin LP. γδT Cells and Related Diseases. Am J Reprod Immunol 2016;75:609-18. [PMID: 26833725 DOI: 10.1111/aji.12495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
157 Peng H, Tian Z. NK cells in liver homeostasis and viral hepatitis. Sci China Life Sci 2018;61:1477-85. [PMID: 30421296 DOI: 10.1007/s11427-018-9407-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
158 Zhang L, Zhang ZG, Long X, Liu FL, Zhang WG. Severe Complications After Splenic Artery Embolization for Portal Hypertension Due to Hepatic Cirrhosis. Risk Manag Healthc Policy 2020;13:135-40. [PMID: 32110126 DOI: 10.2147/RMHP.S234628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Aghbash PS, Eslami N, Shirvaliloo M, Baghi HB. Viral coinfections in COVID-19. J Med Virol 2021;93:5310-22. [PMID: 34032294 DOI: 10.1002/jmv.27102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Han JW, Shin EC. Liver-Resident Memory CD8+ T Cells: Possible Roles in Chronic HBV Infection. Int J Mol Sci 2020;22:E283. [PMID: 33396596 DOI: 10.3390/ijms22010283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Schuch A, Zecher BF, Müller PA, Correia MP, Daul F, Rennert C, Tauber C, Schlitt K, Boettler T, Neumann-Haefelin C, Hengel H, Pircher H, Cerwenka A, Thimme R, Hofmann M. NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection. J Hepatol 2019;70:351-60. [PMID: 30342116 DOI: 10.1016/j.jhep.2018.10.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
162 Fu Q, Yan S, Wang L, Duan X, Wang L, Wang Y, Wu T, Wang X, An J, Zhang Y, Zhou Q, Zhan L. Hepatic NK cell-mediated hypersensitivity to ConA-induced liver injury in mouse liver expressing hepatitis C virus polyprotein. Oncotarget 2017;8:52178-92. [PMID: 28881722 DOI: 10.18632/oncotarget.11052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
163 Bolte FJ, Rehermann B. Tissue-resident T cells in hepatitis B: A new target for cure? J Exp Med 2017;214:1564-6. [PMID: 28526760 DOI: 10.1084/jem.20170842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
164 Depla M, Pelletier S, Bédard N, Brunaud C, Bruneau J, Shoukry NH. IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. Immun Inflamm Dis 2016;4:376-88. [PMID: 27621819 DOI: 10.1002/iid3.122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
165 Guo C, Shen X, Fu B, Liu Y, Chen Y, Ni F, Ye Y, Sun R, Li J, Tian Z, Wei H. CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients. Sci Rep 2016;6:25567. [PMID: 27174425 DOI: 10.1038/srep25567] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
166 Zehn D, Utzschneider DT, Thimme R. Immune-surveillance through exhausted effector T-cells. Curr Opin Virol 2016;16:49-54. [PMID: 26826950 DOI: 10.1016/j.coviro.2016.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
167 Zhang X, Xu J, Ke X, Zhang S, Huang P, Xu T, Huang L, Lou J, Shi X, Sun R, Wang F, Pan S. Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer. Cancer Immunol Immunother 2015;64:275-86. [PMID: 25376541 DOI: 10.1007/s00262-014-1632-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
168 Bhattacharya A, Hegazy AN, Deigendesch N, Kosack L, Cupovic J, Kandasamy RK, Hildebrandt A, Merkler D, Kühl AA, Vilagos B, Schliehe C, Panse I, Khamina K, Baazim H, Arnold I, Flatz L, Xu HC, Lang PA, Aderem A, Takaoka A, Superti-Furga G, Colinge J, Ludewig B, Löhning M, Bergthaler A. Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity 2015;43:974-86. [PMID: 26588782 DOI: 10.1016/j.immuni.2015.10.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
169 Lepiller Q, Soulier E, Li Q, Lambotin M, Barths J, Fuchs D, Stoll-Keller F, Liang TJ, Barth H. Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection. J Innate Immun. 2015;7:530-544. [PMID: 25792183 DOI: 10.1159/000375161] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
170 Shmeleva EV, Colucci F. Maternal natural killer cells at the intersection between reproduction and mucosal immunity. Mucosal Immunol 2021;14:991-1005. [PMID: 33903735 DOI: 10.1038/s41385-020-00374-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
171 Goody MF, Sullivan C, Kim CH. Studying the immune response to human viral infections using zebrafish. Dev Comp Immunol 2014;46:84-95. [PMID: 24718256 DOI: 10.1016/j.dci.2014.03.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
172 Bengsch B, Thimme R. Balance lost: T cell immunity in progressive HBV infection. Hepatol Int 2014;8:7-9. [PMID: 26202401 DOI: 10.1007/s12072-013-9506-4] [Reference Citation Analysis]
173 Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, Luo X, Chen T, Ning Q. CD56 bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a. J Viral Hepat 2018;25:1352-62. [DOI: 10.1111/jvh.12946] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
174 Ferrari C, Boni C, Rossi M, Vecchi A, Barili V, Laccabue D, Fisicaro P, Missale G. T cell regulation in HBV-related chronic liver disease. Journal of Hepatology 2017;66:1096-8. [DOI: 10.1016/j.jhep.2016.10.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
175 Guan Y, Li W, Hou Z, Han Q, Lan P, Zhang J, Tian Z, Zhang C. HBV suppresses expression of MICA/B on hepatoma cells through up-regulation of transcription factors GATA2 and GATA3 to escape from NK cell surveillance. Oncotarget 2016;7:56107-19. [PMID: 27528231 DOI: 10.18632/oncotarget.11271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
176 Heiberg IL, Pallett LJ, Winther TN, Høgh B, Maini MK, Peppa D. Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clin Exp Immunol 2015;179:466-76. [PMID: 25311087 DOI: 10.1111/cei.12470] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
177 Kremsdorf D, Strick-Marchand H. Modeling hepatitis virus infections and treatment strategies in humanized mice. Curr Opin Virol 2017;25:119-25. [PMID: 28858692 DOI: 10.1016/j.coviro.2017.07.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
178 Peng H, Tian Z. Tissue-resident natural killer cells in the livers. Sci China Life Sci 2016;59:1218-23. [DOI: 10.1007/s11427-016-0334-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
179 Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-haefelin C, Kukolj G, Böcher W, Thimme R. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. Journal of Hepatology 2014;61:538-43. [DOI: 10.1016/j.jhep.2014.05.043] [Cited by in Crossref: 175] [Cited by in F6Publishing: 169] [Article Influence: 21.9] [Reference Citation Analysis]
180 Kalathil SG, Thanavala Y. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells 2021;10:1332. [PMID: 34071188 DOI: 10.3390/cells10061332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Kaczmarek DJ, Kokordelis P, Krämer B, Glässner A, Wolter F, Goeser F, Lutz P, Schwarze-Zander C, Boesecke C, Strassburg CP, Rockstroh JK, Spengler U, Nattermann J. Alterations of the NK cell pool in HIV/HCV co-infection. PLoS One 2017;12:e0174465. [PMID: 28380039 DOI: 10.1371/journal.pone.0174465] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
182 Wan Z, Liu J, Hu F, Shui J, Li L, Wang H, Tang X, Hu C, Liang Y, Zhou Y, Cai W, Tang S. Evidence that the second human pegivirus (HPgV-2) is primarily a lymphotropic virus and can replicate independent of HCV replication. Emerg Microbes Infect 2020;9:485-95. [PMID: 32100631 DOI: 10.1080/22221751.2020.1730247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Lu J, Wang X, Zhu Y, Ma L, Zheng S, Hu Z, Chen X. Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. Gut Liver 2021;15:887-94. [PMID: 34446613 DOI: 10.5009/gnl21001] [Reference Citation Analysis]
184 Li X, Gu Y, Guo X, Gu L, Zhou L, Wu X, Wang X, Stamataki Z, Huang Y. A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection. Sci Rep 2017;7:5866. [PMID: 28725030 DOI: 10.1038/s41598-017-06192-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
185 Gallo A, Miele M, Badami E, Conaldi PG. Molecular and cellular interplay in virus-induced tumors in solid organ recipients. Cellular Immunology 2019;343:103770. [DOI: 10.1016/j.cellimm.2018.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
186 Mishra R, Welsh R, Szomolanyi-Tsuda E. NK cells and virus-related cancers. Crit Rev Oncog 2014;19:107-19. [PMID: 24941377 DOI: 10.1615/critrevoncog.2014010866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
187 Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M. Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology. 2016;63:83-94. [PMID: 26458241 DOI: 10.1002/hep.28282] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
188 Nishio A, Rehermann B. Virus-Induced Interferon Regulates the Urea Cycle. Immunity 2019;51:975-7. [PMID: 31951542 DOI: 10.1016/j.immuni.2019.11.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
189 Rogalska-Taranta M, Markova AA, Taranta A, Lunemann S, Schlaphoff V, Flisiak R, Manns MP, Cornberg M, Kraft AR, Wedemeyer H. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. J Leukoc Biol 2015;98:283-94. [PMID: 26034208 DOI: 10.1189/jlb.4A1014-520R] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
190 Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, Karmele EP, McNally JP, Moran MT, Brooks TR, Yaqoob F, Rydyznski CE. Roles of natural killer cells in antiviral immunity. Curr Opin Virol. 2016;16:15-23. [PMID: 26590692 DOI: 10.1016/j.coviro.2015.10.008] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 11.3] [Reference Citation Analysis]
191 Wisskirchen K, Metzger K, Schreiber S, Asen T, Weigand L, Dargel C, Witter K, Kieback E, Sprinzl MF, Uckert W, Schiemann M, Busch DH, Krackhardt AM, Protzer U. Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use. PLoS One 2017;12:e0182936. [PMID: 28792537 DOI: 10.1371/journal.pone.0182936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
192 Dusséaux M, Masse-Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L, Neuveut C, Soussan P, Roingeard P, Kremsdorf D, Di Santo JP, Strick-Marchand H. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology 2017;153:1647-1661.e9. [PMID: 28851562 DOI: 10.1053/j.gastro.2017.08.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
193 Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol 2016;30:93-105. [PMID: 27570126 DOI: 10.1016/j.coph.2016.07.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
194 Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41-46. [PMID: 26262886 DOI: 10.1016/j.coviro.2015.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
195 Nel I, Lucar O, Petitdemange C, Béziat V, Lapalus M, Bédossa P, Debré P, Asselah T, Marcellin P, Vieillard V. Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection. Medicine (Baltimore) 2016;95:e3678. [PMID: 27175704 DOI: 10.1097/MD.0000000000003678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
196 Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM;  Hepatitis B Research Network. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.. Gastroenterology. 2016;150:684-695.e5. [PMID: 26684441 DOI: 10.1053/j.gastro.2015.11.050] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 14.0] [Reference Citation Analysis]
197 Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P, Martin C, van Rooijen N, Ochando JC, Randolph GJ, Luedde T, Ginhoux F, Kurts C, Trautwein C, Tacke F. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62:279-291. [PMID: 25810240 DOI: 10.1002/hep.27793] [Cited by in Crossref: 162] [Cited by in F6Publishing: 151] [Article Influence: 23.1] [Reference Citation Analysis]
198 Rehermann B. Natural Killer Cells in Viral Hepatitis. Cell Mol Gastroenterol Hepatol 2015;1:578-88. [PMID: 26682281 DOI: 10.1016/j.jcmgh.2015.09.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
199 Tseng TC, Huang LR. Immunopathogenesis of Hepatitis B Virus. J Infect Dis. 2017;216:S765-S770. [PMID: 29156047 DOI: 10.1093/infdis/jix356] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
200 Zhou P, Zhong XZ, Liao HH. New immunotherapy strategies for antiviral treatment of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2016; 24(12): 1832-1839 [DOI: 10.11569/wcjd.v24.i12.1832] [Reference Citation Analysis]
201 Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C, Ortiz C, Bonaccorsi-Riani E, Brander C, Bauer T, Protzer U, Jaeckel E, Taubert R, Forns X, Navasa M, Berenguer M, Rimola A, Lozano JJ, Sánchez-Fueyo A. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. Sci Transl Med 2014;6:242ra81. [PMID: 24964989 DOI: 10.1126/scitranslmed.3008793] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
202 Hofmann M, Thimme R. iNKT cells in chronic HBV: a balancing act. Hepatol Int 2016;10:535-7. [DOI: 10.1007/s12072-016-9739-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
203 Rehermann B. Peptide-dependent HLA-KIR-mediated regulation of NK cell function. J Hepatol 2016;65:237-9. [PMID: 27212248 DOI: 10.1016/j.jhep.2016.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
204 Badshah Y, Arshad N, Khan M, Jannat A, Hayat H. Association of Interleukin-4 (-590 C/T) and Interleukin-6 (-174 G/C) Polymorphism in Pathogenesis and Prognosis of Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research 2018;38:559-65. [DOI: 10.1089/jir.2018.0081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
205 Pedersen J, Lundbo LF, Krarup H, Bukh J, Weis N. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection. J Med Virol 2016;88:1791-803. [PMID: 27027386 DOI: 10.1002/jmv.24537] [Reference Citation Analysis]
206 Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol 2017; 9(36): 1305-1314 [PMID: 29359013 DOI: 10.4254/wjh.v9.i36.1305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
207 Hengst J, Strunz B, Deterding K, Ljunggren H, Leeansyah E, Manns MP, Cornberg M, Sandberg JK, Wedemeyer H, Björkström NK. Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy. Eur J Immunol 2016;46:2204-10. [DOI: 10.1002/eji.201646447] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 15.7] [Reference Citation Analysis]
208 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
209 Kao WY, Yang SH, Liu WJ, Yeh MY, Lin CL, Liu CJ, Huang CJ, Lin SM, Lee SD, Chen PJ, Yu MW. Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. Mol Carcinog 2017;56:425-35. [PMID: 27254796 DOI: 10.1002/mc.22505] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
210 Khan AR, Amu S, Saunders SP, Fallon PG. The Generation of Regulatory B Cells by Helminth Parasites. In: Vitale G, Mion F, editors. Regulatory B Cells. New York: Springer; 2014. pp. 143-62. [DOI: 10.1007/978-1-4939-1161-5_11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
211 Yuan W, Huang D, Wu D, Chen Y, Ma K, Han M, Luo X, Yan W, Ning Q. Peg IFN-ɑ Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-γ in Chronic Hepatitis B. J Infect Dis 2021:jiab216. [PMID: 33870432 DOI: 10.1093/infdis/jiab216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, Sharma P, Deenen R, Köhrer K, Rahbar R, Diefenbach A, Gibbert K, Löhning M, Höcker L, Waibler Z, Häussinger D, Mak TW, Ohashi PS, Lang KS, Lang PA. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 2014;40:949-60. [PMID: 24909887 DOI: 10.1016/j.immuni.2014.05.004] [Cited by in Crossref: 149] [Cited by in F6Publishing: 143] [Article Influence: 18.6] [Reference Citation Analysis]
213 Tan AT, Schreiber S. Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research 2020;176:104748. [DOI: 10.1016/j.antiviral.2020.104748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
214 Collister M, Ellison C, Li Q, Minuk GY, Rempel JD, Kung SK. The Influence of Hepatitis C Viral Loads on Natural Killer Cell Function. Gastroenterology Res 2019;12:8-15. [PMID: 30834029 DOI: 10.14740/gr1081w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
215 Ma Q, Dong X, Liu S, Zhong T, Sun D, Zong L, Zhao C, Lu Q, Zhang M, Gao Y, Ye Y, Cheng J, Xu Y, Zheng M. Hepatitis B e Antigen Induces NKG2A+ Natural Killer Cell Dysfunction via Regulatory T Cell-Derived Interleukin 10 in Chronic Hepatitis B Virus Infection. Front Cell Dev Biol 2020;8:421. [PMID: 32582704 DOI: 10.3389/fcell.2020.00421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
216 Ariede JR, Pardini MI, Silva GF, Grotto RM. Platelets can be a biological compartment for the Hepatitis C Virus. Braz J Microbiol 2015;46:627-9. [PMID: 26273283 DOI: 10.1590/S1517-838246220140553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
217 Szereday L, Meggyes M, Berki T, Miseta A, Farkas N, Gervain J, Par A, Par G. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C. Clin Exp Med 2020;20:219-30. [PMID: 32108916 DOI: 10.1007/s10238-020-00618-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
218 Nauclér CS, Geisler J, Vetvik K. The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications. Oncotarget 2019;10:4333-47. [PMID: 31303966 DOI: 10.18632/oncotarget.27016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
219 Zhang QF, Shao JY, Yin WW, Xia Y, Chen L, Wang X, Hu HD, Hu P, Ren H, Zhang DZ. Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160171. [PMID: 27513564 DOI: 10.1371/journal.pone.0160171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
220 Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, Ghany M, Rehermann B. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015;149:190-200.e2. [PMID: 25754160 DOI: 10.1053/j.gastro.2015.03.004] [Cited by in Crossref: 170] [Cited by in F6Publishing: 160] [Article Influence: 24.3] [Reference Citation Analysis]
221 Markova AA, Mihm U, Schlaphoff V, Lunemann S, Filmann N, Bremer B, Berg T, Sarrazin C, Zeuzem S, Manns MP. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C. PLoS One. 2014;9:e94512. [PMID: 24751903 DOI: 10.1371/journal.pone.0094512] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
222 Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014;40:13-24. [PMID: 24439265 DOI: 10.1016/j.immuni.2013.12.010] [Cited by in Crossref: 180] [Cited by in F6Publishing: 169] [Article Influence: 22.5] [Reference Citation Analysis]
223 Jin X, Yan ZH, Lu L, Lu S, Zhang G, Lin W. Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:759292. [PMID: 34782855 DOI: 10.3389/fmed.2021.759292] [Reference Citation Analysis]
224 Shabani Z, Bagheri M, Zare-Bidaki M, Hassanshahi G, Arababadi MK, Mohammadi Nejad M, Kennedy D. NK cells in hepatitis B virus infection: a potent target for immunotherapy. Arch Virol. 2014;159:1555-1565. [PMID: 24445811 DOI: 10.1007/s00705-013-1965-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
225 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Reference Citation Analysis]
226 Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM. Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol 2014;88:3678-94. [PMID: 24429362 DOI: 10.1128/JVI.03540-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
227 Bhattarai N, McLinden JH, Xiang J, Kaufman TM, Stapleton JT. Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation. PLoS Pathog 2015;11:e1005183. [PMID: 26421924 DOI: 10.1371/journal.ppat.1005183] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
228 Barili V, Boni C, Rossi M, Vecchi A, Zecca A, Penna A, Missale G, Ferrari C, Fisicaro P. Metabolic regulation of the HBV-specific T cell function. Antiviral Res 2021;185:104989. [PMID: 33248194 DOI: 10.1016/j.antiviral.2020.104989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
229 Bertol BC, Dias FC, Debortoli G, Souto BM, Mendonça PB, Araújo RC, Santana RC, Ramalho LNZ, Castelli EC, Martinelli ALC, Mendes-Junior CT, Carosella ED, Donadi EA, Moreau P. HLA-G liver expression and HLA-G extended haplotypes are associated with chronic hepatitis C in HIV-negative and HIV-coinfected patients. Clin Immunol 2020;217:108482. [PMID: 32470543 DOI: 10.1016/j.clim.2020.108482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
231 Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol 2021;18:461-71. [PMID: 33432062 DOI: 10.1038/s41423-020-00601-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, Ghany M, Rehermann B. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. Gastroenterology. 2017;153:1392-1403.e2. [PMID: 28780074 DOI: 10.1053/j.gastro.2017.07.043] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
233 Gao F, Wang H, Li X, Guo F, Yuan Y, Wang X, Zhang Y, Bai G. Alteration of the Immune Microenvironment in HBsAg and HBeAg Dual-Positive Pregnant Women Presenting a High HBV Viral Load. J Inflamm Res 2021;14:5619-32. [PMID: 34764667 DOI: 10.2147/JIR.S337561] [Reference Citation Analysis]
234 Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, Imhof H, Grimm D, Steiger K, Mogler C, Heikenwalder M, Michel ML, Guzman CA, Milstein S, Sepp-Lorenzino L, Knolle P, Protzer U. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. Gastroenterology 2020;158:1762-1775.e9. [PMID: 32001321 DOI: 10.1053/j.gastro.2020.01.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
235 Barili V, Fisicaro P, Montanini B, Acerbi G, Filippi A, Forleo G, Romualdi C, Ferracin M, Guerrieri F, Pedrazzi G, Boni C, Rossi M, Vecchi A, Penna A, Zecca A, Mori C, Orlandini A, Negri E, Pesci M, Massari M, Missale G, Levrero M, Ottonello S, Ferrari C. Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nat Commun. 2020;11:604. [PMID: 32001678 DOI: 10.1038/s41467-019-14137-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
236 Toson el-SA, Shiha GE, El-Mezayen HA, El-Sharkawy AM. Diagnostic performance of T lymphocyte subpopulations in assessment of liver fibrosis stages in hepatitis C virus patients: simple noninvasive score. Eur J Gastroenterol Hepatol 2016;28:931-9. [PMID: 27159125 DOI: 10.1097/MEG.0000000000000656] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
237 Wijaya RS, Read SA, Selvamani SP, Schibeci S, Azardaryany MK, Ong A, van der Poorten D, Lin R, Douglas MW, George J, Ahlenstiel G. Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. J Infect Dis 2021;223:1183-95. [PMID: 32777077 DOI: 10.1093/infdis/jiaa492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
238 Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol. 2014;96:535-548. [PMID: 25015956 DOI: 10.1189/jlb.4ri0214-126r] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
239 Lunemann S, Martrus G, Hölzemer A, Chapel A, Ziegler M, Körner C, Garcia Beltran W, Carrington M, Wedemeyer H, Altfeld M. Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function. J Hepatol 2016;65:252-8. [PMID: 27057987 DOI: 10.1016/j.jhep.2016.03.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
240 Healy K, Pasetto A, Sobkowiak MJ, Soon CF, Cornberg M, Aleman S, Sällberg Chen M. Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. Cells 2020;9:E1471. [PMID: 32560123 DOI: 10.3390/cells9061471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
241 Means S, Ali MA, Ho H, Heffernan J. Mathematical Modeling for Hepatitis B Virus: Would Spatial Effects Play a Role and How to Model It? Front Physiol 2020;11:146. [PMID: 32158403 DOI: 10.3389/fphys.2020.00146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Horner SM. Activation and Evasion of Antiviral Innate Immunity by Hepatitis C Virus. J Mol Biol. 2014;426:1198-1209. [PMID: 24184198 DOI: 10.1016/j.jmb.2013.10.032] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
243 Chen SR, Chen XP, Lu JJ, Wang Y, Wang YT. Potent natural products and herbal medicines for treating liver fibrosis. Chin Med. 2015;10:7. [PMID: 25897319 DOI: 10.1186/s13020-015-0036-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
244 Serti E, Park H, Keane M, O’Keefe AC, Rivera E, Liang TJ, Ghany M, Rehrmann B. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Gut. 2016; Epub ahead of print. [PMID: 26733671 DOI: 10.1136/gutjnl-2015-310033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
245 Smith C, Khanna R. Adoptive cellular immunotherapy for virus‐associated cancers: a new paradigm in personalized medicine. Immunol Cell Biol 2017;95:364-71. [DOI: 10.1038/icb.2016.127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
246 Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis. Hosp Pract (1995). 2019;47:105-110. [PMID: 31018721 DOI: 10.1080/21548331.2019.1612066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
247 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 48.2] [Reference Citation Analysis]
248 Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014;124:3352-3363. [PMID: 24983321 DOI: 10.1172/jci75938] [Cited by in Crossref: 144] [Cited by in F6Publishing: 88] [Article Influence: 18.0] [Reference Citation Analysis]
249 Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin ME, Mavilio D. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun. 2016;66:40-50. [PMID: 26330348 DOI: 10.1016/j.jaut.2015.08.011] [Cited by in Crossref: 130] [Cited by in F6Publishing: 129] [Article Influence: 18.6] [Reference Citation Analysis]
250 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 11.4] [Reference Citation Analysis]
251 Yin W, Tong S, Zhang Q, Shao J, Liu Q, Peng H, Hu H, Peng M, Hu P, Ren H, Tian Z, Zhang D. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep 2016;6:26296. [PMID: 27192960 DOI: 10.1038/srep26296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
252 O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes Immun 2016;17:328-34. [PMID: 27307212 DOI: 10.1038/gene.2016.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
253 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
254 Rinker F, Zimmer CL, Höner zu Siederdissen C, Manns MP, Kraft AR, Wedemeyer H, Björkström NK, Cornberg M. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. Journal of Hepatology 2018;69:584-93. [DOI: 10.1016/j.jhep.2018.05.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
255 Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13:88-110. [PMID: 26758786 DOI: 10.1038/nrgastro.2015.200] [Cited by in Crossref: 425] [Cited by in F6Publishing: 405] [Article Influence: 70.8] [Reference Citation Analysis]
256 Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306-321. [PMID: 28317925 DOI: 10.1038/nri.2017.11] [Cited by in Crossref: 442] [Cited by in F6Publishing: 431] [Article Influence: 88.4] [Reference Citation Analysis]
257 Bhattarai N, McLinden JH, Xiang J, Mathahs MM, Schmidt WN, Kaufman TM, Stapleton JT. Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. PLoS Pathog 2017;13:e1006232. [PMID: 28235043 DOI: 10.1371/journal.ppat.1006232] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
258 Liu HZ, Deng W, Li JL, Tang YM, Zhang LT, Cui Y, Liang XQ. Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. Oncotarget 2016;7:77558-64. [PMID: 27813499 DOI: 10.18632/oncotarget.13041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
259 Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
260 Khoshdel-Rad N, Zahmatkesh E, Bikmulina P, Peshkova M, Kosheleva N, Bezrukov EA, Sukhanov RB, Solovieva A, Shpichka A, Timashev P, Vosough M. Modeling Hepatotropic Viral Infections: Cells vs. Animals. Cells 2021;10:1726. [PMID: 34359899 DOI: 10.3390/cells10071726] [Reference Citation Analysis]
261 Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M. Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses 2019;11:E406. [PMID: 31052463 DOI: 10.3390/v11050406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
262 Yamazaki T, Umemura T, Joshita S, Yoshizawa K, Tanaka E, Ota M. A cis-eQTL of HLA-DPB1 Affects Susceptibility to Type 1 Autoimmune Hepatitis. Sci Rep 2018;8:11924. [PMID: 30093645 DOI: 10.1038/s41598-018-30406-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
263 Gonzalez-Aldaco K, Rebello Pinho JR, Roman S, Gleyzer K, Fierro NA, Oyakawa L, Ramos-Lopez O, Ferraz Santana RA, Sitnik R, Panduro A. Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. PLoS One. 2016;11:e0146258. [PMID: 26741362 DOI: 10.1371/journal.pone.0146258] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
264 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
265 Khlaiphuengsin A, Chuaypen N, Sodsai P, Reantragoon R, Han WM, Avihingsanon A, Tangkijvanich P. Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection. PLoS One 2020;15:e0244112. [PMID: 33382729 DOI: 10.1371/journal.pone.0244112] [Reference Citation Analysis]
266 Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018;69:18-24. [PMID: 29505844 DOI: 10.1016/j.jhep.2018.02.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 14.5] [Reference Citation Analysis]
267 Miot C, Beaumont E, Duluc D, Le Guillou-guillemette H, Preisser L, Garo E, Blanchard S, Hubert Fouchard I, Créminon C, Lamourette P, Fremaux I, Calès P, Lunel-fabiani F, Boursier J, Braum O, Fickenscher H, Roingeard P, Delneste Y, Jeannin P. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut 2015;64:1466-75. [DOI: 10.1136/gutjnl-2013-306604] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
268 Masselli E, Vaccarezza M, Carubbi C, Pozzi G, Presta V, Mirandola P, Vitale M. NK cells: A double edge sword against SARS-CoV-2. Adv Biol Regul 2020;77:100737. [PMID: 32773100 DOI: 10.1016/j.jbior.2020.100737] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
269 Elpek G&. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol 2014; 20(23): 7260-7276 [PMID: 24966597 DOI: 10.3748/wjg.v20.i23.7260] [Cited by in CrossRef: 173] [Cited by in F6Publishing: 156] [Article Influence: 21.6] [Reference Citation Analysis]
270 Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sällberg M, Lohmann V, Koh S, Bertoletti A, Chen M. Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. J Virol 2017;91:e00010-17. [PMID: 28228595 DOI: 10.1128/JVI.00010-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
271 Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol 2021; 27(9): 782-793 [PMID: 33727770 DOI: 10.3748/wjg.v27.i9.782] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
272 Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C. TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. Gastroenterology 2018;154:1764-1777.e7. [DOI: 10.1053/j.gastro.2018.01.030] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 15.8] [Reference Citation Analysis]
273 Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut 2014;63:369-75. [DOI: 10.1136/gutjnl-2013-306102] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
274 Billerbeck E, Mommersteeg MC, Shlomai A, Xiao JW, Andrus L, Bhatta A, Vercauteren K, Michailidis E, Dorner M, Krishnan A, Charlton MR, Chiriboga L, Rice CM, de Jong YP. Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. J Hepatol 2016;65:334-43. [PMID: 27151182 DOI: 10.1016/j.jhep.2016.04.022] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
275 Sällberg M, Pasetto A. Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation. Front Immunol 2020;11:552. [PMID: 32292409 DOI: 10.3389/fimmu.2020.00552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 He Y, Zhou Y, Wang H, Yin J, Chang Y, Hu P, Ren H, Xu H. Identifying potential biomarkers in hepatitis B virus infection and its response to the antiviral therapy by integrated bioinformatic analysis. J Cell Mol Med 2021;25:6558-72. [PMID: 34041839 DOI: 10.1111/jcmm.16655] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
277 Lunemann S, Langeneckert AE, Martrus G, Hess LU, Salzberger W, Ziegler AE, Löbl SM, Poch T, Ravichandran G, Sauter J, Schmidt AH, Schramm C, Oldhafer KJ, Altfeld M, Körner C. Human liver-derived CXCR6+ NK cells are predominantly educated through NKG2A and show reduced cytokine production. J Leukoc Biol 2019;105:1331-40. [PMID: 30779432 DOI: 10.1002/JLB.1MA1118-428R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
278 Nath PR, Gangaplara A, Pal-Nath D, Mandal A, Maric D, Sipes JM, Cam M, Shevach EM, Roberts DD. CD47 Expression in Natural Killer Cells Regulates Homeostasis and Modulates Immune Response to Lymphocytic Choriomeningitis Virus. Front Immunol 2018;9:2985. [PMID: 30643501 DOI: 10.3389/fimmu.2018.02985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
279 Watanabe T, Hamada-Tsutsumi S, Yokomaku Y, Imamura J, Sugiura W, Tanaka Y. Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection. Antimicrob Agents Chemother 2015;59:1292-8. [PMID: 25512419 DOI: 10.1128/AAC.04459-14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
280 Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology. 2015;61:1066-1079. [PMID: 25066777 DOI: 10.1002/hep.27332] [Cited by in Crossref: 419] [Cited by in F6Publishing: 422] [Article Influence: 59.9] [Reference Citation Analysis]
281 Liu Y, Huang R, Xiong Y, Zhao Q, Chen G, Xia J, Wu C. Soluble CD40 ligand-activated B cells from patients with chronic hepatitis B virus infection as antigen presenting cells to induce hepatitis B virus specific cytotoxic T lymphocytes. Biochem Biophys Res Commun 2014;450:61-6. [PMID: 24866241 DOI: 10.1016/j.bbrc.2014.05.080] [Reference Citation Analysis]
282 Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol. 2014;61:1212-1219. [PMID: 25016223 DOI: 10.1016/j.jhep.2014.07.005] [Cited by in Crossref: 150] [Cited by in F6Publishing: 147] [Article Influence: 18.8] [Reference Citation Analysis]
283 Cho YJ, Lee HH, Kang H, Cho H. Cytokine-Modulated Natural Killer Cells Differentially Regulate the Activity of the Hepatitis C Virus. Int J Mol Sci 2018;19:E2771. [PMID: 30223493 DOI: 10.3390/ijms19092771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
284 Knolle PA, Huang LR, Kosinska A, Wohlleber D, Protzer U. Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines (Basel) 2021;9:1333. [PMID: 34835264 DOI: 10.3390/vaccines9111333] [Reference Citation Analysis]
285 Feuth T, Van Baarle D, Hoepelman AIM, Van Erpecum KJ, Siersema PD, Arends JE. Activation of extrinsic apoptosis pathway in HCV monoinfected and HIV–HCV coinfected patients, irrespective of liver disease severity. Apoptosis 2014;19:1128-35. [DOI: 10.1007/s10495-014-0992-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
286 Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology. 2014;146:1193-1207. [PMID: 24412289 DOI: 10.1053/j.gastro.2013.12.036] [Cited by in Crossref: 129] [Cited by in F6Publishing: 125] [Article Influence: 16.1] [Reference Citation Analysis]
287 Manske K, Schneider A, Ko C, Knolle PA, Steiger K, Protzer U, Wohlleber D. In Vivo Bioluminescence Imaging of HBV Replicating Hepatocytes Allows for the Monitoring of Anti-Viral Immunity. Viruses 2021;13:2273. [PMID: 34835079 DOI: 10.3390/v13112273] [Reference Citation Analysis]
288 Cichocki F, Sitnicka E, Bryceson YT. NK cell development and function – Plasticity and redundancy unleashed. Seminars in Immunology 2014;26:114-26. [DOI: 10.1016/j.smim.2014.02.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
289 Tian Z. Outflanking HCV. Nat Immunol 2014;15:6-8. [PMID: 24352316 DOI: 10.1038/ni.2783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
290 Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. 2014;105:100-111. [PMID: 24583033 DOI: 10.1016/j.antiviral.2014.02.013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 11.4] [Reference Citation Analysis]
291 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
292 Goyal A, Murray JM. Modelling the Impact of Cell-To-Cell Transmission in Hepatitis B Virus. PLoS One 2016;11:e0161978. [PMID: 27560827 DOI: 10.1371/journal.pone.0161978] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
293 Huang QT, Chen JH, Zhong M, Xu YY, Cai CX, Wei SS, Hang LL, Liu Q, Yu YH. The risk of placental abruption and placenta previa in pregnant women with chronic hepatitis B viral infection: a systematic review and meta-analysis. Placenta. 2014;35:539-545. [PMID: 24934739 DOI: 10.1016/j.placenta.2014.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
294 Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. [PMID: 31548710 DOI: 10.1038/s41575-019-0196-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
295 Nakamura I, Asano T, Asabe S, Ando M, Sano T, Miyata Y, Taira J, Sugimoto K, Imai Y, Moriyasu F, Imawari M. Restoration of natural killer cell activity by pegylated interferon-alpha/ribavirin therapy in chronic hepatitis C patient: NK activity restoration by PEG IFN/RBV in CHC. Hepatol Res 2015;45:107-12. [DOI: 10.1111/hepr.12322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
296 Fang P, Zhang D, Cheng Z, Yan C, Jiang X, Kruger WD, Meng S, Arning E, Bottiglieri T, Choi ET. Hyperhomocysteinemia potentiates hyperglycemia-induced inflammatory monocyte differentiation and atherosclerosis. Diabetes. 2014;63:4275-4290. [PMID: 25008174 DOI: 10.2337/db14-0809] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 6.6] [Reference Citation Analysis]
297 Li Y, Wang JJ, Gao S, Liu Q, Bai J, Zhao XQ, Hao YH, Ding HH, Zhu F, Yang DL, Zhao XP. Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B. PLoS One. 2014;9:e86927. [PMID: 24520324 DOI: 10.1371/journal.pone.0086927] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]